Sangamo Therapeutics Statistics
Share Statistics
Sangamo Therapeutics has 245.4M
shares outstanding. The number of shares has increased by 8.29%
in one year.
| Shares Outstanding | 245.4M |
| Shares Change (YoY) | 8.29% |
| Shares Change (QoQ) | 7.7% |
| Owned by Institutions (%) | 29.52% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 10,362 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 28.25M, so 12.57% of the outstanding
shares have been sold short.
| Short Interest | 28.25M |
| Short % of Shares Out | 12.57% |
| Short % of Float | 12.64% |
| Short Ratio (days to cover) | 7.04 |
Valuation Ratios
The PE ratio is -2.1 and the forward
PE ratio is -1.37.
Sangamo Therapeutics's PEG ratio is
0.03.
| PE Ratio | -2.1 |
| Forward PE | -1.37 |
| PS Ratio | 3.56 |
| Forward PS | 0.4 |
| PB Ratio | 9.04 |
| P/FCF Ratio | -3.05 |
| PEG Ratio | 0.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Sangamo Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.13,
with a Debt / Equity ratio of 1.34.
| Current Ratio | 1.13 |
| Quick Ratio | 1.13 |
| Debt / Equity | 1.34 |
| Debt / EBITDA | -0.34 |
| Debt / FCF | -0.45 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $315,846.99 |
| Profits Per Employee | $-535,196.72 |
| Employee Count | 183 |
| Asset Turnover | 0.57 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -167K |
| Effective Tax Rate | 0.17% |
Stock Price Statistics
The stock price has increased by -21.03% in the
last 52 weeks. The beta is 1.46, so Sangamo Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.46 |
| 52-Week Price Change | -21.03% |
| 50-Day Moving Average | 0.7 |
| 200-Day Moving Average | 1.19 |
| Relative Strength Index (RSI) | 36.07 |
| Average Volume (20 Days) | 6,984,868 |
Income Statement
In the last 12 months, Sangamo Therapeutics had revenue of 57.8M
and earned -97.94M
in profits. Earnings per share was -0.49.
| Revenue | 57.8M |
| Gross Profit | 48.44M |
| Operating Income | -103.97M |
| Net Income | -97.94M |
| EBITDA | -88.75M |
| EBIT | -98.45M |
| Earnings Per Share (EPS) | -0.49 |
Full Income StatementBalance Sheet
The company has 41.92M in cash and 30.57M in
debt, giving a net cash position of 11.35M.
| Cash & Cash Equivalents | 41.92M |
| Total Debt | 30.57M |
| Net Cash | 11.35M |
| Retained Earnings | -1.5B |
| Total Assets | 86.17M |
| Working Capital | -11.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -67.14M
and capital expenditures -267K, giving a free cash flow of -67.41M.
| Operating Cash Flow | -67.14M |
| Capital Expenditures | -267K |
| Free Cash Flow | -67.41M |
| FCF Per Share | -0.33 |
Full Cash Flow StatementMargins
Gross margin is 83.8%, with operating and profit margins of -179.88% and -169.45%.
| Gross Margin | 83.8% |
| Operating Margin | -179.88% |
| Pretax Margin | -169.74% |
| Profit Margin | -169.45% |
| EBITDA Margin | -153.54% |
| EBIT Margin | -179.88% |
| FCF Margin | -116.62% |
